This pilot open-label study is aimed to assess clinical response in psoriasis patients receiving diverse dose regimens of etanercept, consisting of the same global cumulative dose of etanercept administered over different treatment periods. Eligible patients were assigned sequentially in a 1:1 ratio to receive: etanercept 50 mg once weekly (QW) or 50 mg twice weekly (BIW) for 12 weeks. The final analysis included a total of 72 patients. At week 12 the Psoriasis Area and Severity Index (PASI) and Skindex-29 scores notably improved in both treatment arms, without significant differences between the two groups. The rate of patients attaining a PASI improvement~50% (PASI 50) at week 12 was 92% in the high-dose group. In these patients, etanercept dosage was decreased to 50 mg QW from week 13, with persistence of the PASI 50 response at week 24 in all cases. Thereafter, treatment was discontinued up to week 36 and almost 30% of patients experienced a gradual relapse of their psoriasis within this period. In the low-dose group, the PASI 50 response was observed in 75% of patients. These responders continued to be treated with etanercept 50 mg QW up to week 36 with persistence of the PASI 50 in 100% of cases at week 24 and 93% at week 36. In the low-dose regimen, 8 patients who did not respond at week 12 underwent dose escalation to 50 mg BIW for a further 12 weeks. At week 24, six of these patients gained the PASI 50 response, 4 of whom maintained the response up to week 36, after treatment discontinuation from week 24. Our results confirm that etanercept is very effective and well-tolerated in psoriasis and that the drug dosages and treatment duration may be modulated and adapted to clinical needs in a flexible way.
inflammatory diseases, and interference with several pathogenic pathways through the down-regulation of proinflammatory and proangiogenic cytokines (1) (2) (3) (4) (5) . In this context and among the available TNF inhibitors, etanercept appears to exhibit a unique pattern ofTNF-blockade, consisting in a modulation rather than a mere suppression of the immune response during treatment (4, (6) (7) .
Multiple studies have shown the efficacy of etanercept and other anti-TNF biologicals in psoriasis, with only a few studies conducted on a long-term basis (8) (9) . In particular, early randomized controlled studies with etanercept had an average duration up to 24 weeks (10) (11) . For this reason, since the approval by the European Medicines Agency, the recommended maximum duration of etanercept treatment in psoriasis patients was initially limited to 24 weeks, with the possibility of re-treatment in the occurrence of return of psoriatic lesions. Recently, regulatory authorities have approved the continuous administration of etanercept beyond 24 weeks in psoriasis, highlighting that it may be an appropriate option to control psoriasis in some adult patients (12). The recommended dosage of etanercept for the treatment of psoriasis is 25 mg administered twice weekly (BlW) or 50 mg administered once weekly (QW). The same dose is recommended for re-treatment in any time, whereas over the initial 12 weeks of the first course, 50 mg BIW may be used.
This pilot open-label study is aimed to assess clinical response in patients receiving diverse dose regimens of etanercept. Such regimens resulted in the same global cumulative dose of etanercept administered over different treatment periods.
MATERIALS AND METHODS
This was an open-label observational multicentre study carried out on psoriasis patients candidate for treatment with etanercept. The study followed the principles of the declaration of Helsinki and was consistent with good clinical practice guidelines. Adult male or female patients with moderate to severe psoriasis who were resistant or intolerant to conventional systemic therapies for psoriasis and/or had contraindications to the use of these therapies were evaluated. Moderate to severe psoriasis was defined by the involvement of more than 10% of the body surface area (BSA) and a Psoriasis Area and Severity Index (PASI) value ( 13) of at least 1(). or alternatively by a BSA affected less than 10% but with lesions localized on "problematic" areas. Eligibility was assessed through the exclusion of any absolute or relative contraindications to the use of etanercept, including pregnancy and lactation, history of malignancies or Iymphoproliferative disorders, immune deficiency, connective tissue diseases, demyelinating disorders, heart failure, active and/or chronic infections. Patients with latent tuberculosis and carriers of hepatitis B or C viruses were also excluded from this study. Moreover, only patients naive to biological therapies and without concomitant psoriatic arthritis were considered. Baseline assessments were performed after an adequate wash-out period from previous active treatments (e.g., 2 weeks for topical therapies, and 4 weeks for systemic traditional drugs, phototherapy or sunlight exposure).
Therefore, after giving their informed consent, eligible patients were assigned sequentially in a I: I ratio to receive: i) etanercept 50 mg QW for 12 weeks or ii) 50 mg BIW for 12 weeks.
A total of 75 patients were enrolled and received at least one dose of etanercept. Before week 12, three patients discontinued for administrative reasons and/ or consent withdrawal so that 72 patients, 36 in each treatment arm, were included in the final analysis.
The primary efficacy endpoint was the improvement of PASI of at least 50% as compared to the baseline value (PASI 50). Efficacy results were also reported as the PASI 75 response rate, corresponding to the proportion of patients with a PASI improvement equal or superior to 75%. Relapse was defined as the loss of at least 50% of the PASI improvement obtained at week 12.
Continuation of the study until week 36 was dependent on the response achieved at week 12 in each group. As concerns the high-dose group, patients who did not reach the PASI 50 at week 12 were withdrawn from the study, whereas those who were PASI 50 responders received etanercept 50 mg QW for a further 12 weeks. In case of persistence of the PASI 50 response at week 24, treatment was interrupted and patients were followed-up until relapse to week 36.
As for patients treated with 50 mg QW, subjects who were PASI 50 responders at week 12 continued to be treated with the same dosage up to week 36, whereas nonresponders received etanercept 50 mg BIW from week 13 to week 24. Again, after such a dose escalation, in patients who attained the PASI 50 response at week 24, treatment was stopped and follow-up assessment was performed until relapse up to week 36.
After baseline, clinical assessments were carried out at weeks 12, 24 and 36. At each visit, PASI was measured. At day () and week 12, patients were also requested to fill in the Skindex-29 questionnaire, a reliable and valid tool specifically designed for measuring health-related quality of life in dermatology patients (14) . The questionnaire comprises three scales assessing essential areas: burden of symptoms, social functioning and emotional state. The score of each scale ranges from 0 to 100 (as a percentage of the maximum score obtainable on that scale), and higher scores reflect a worse quality of life. The Italian version of this self-administered questionnaire has been validated (15) (16) .
Adverse events were registered and monitored as required.
Statistical analysis
Descriptive statistics were used as appropriate. Changes of PASI and Skindex-29 scores within a group at each postbaseline visit as compared to the baseline were analysed using the Wilcoxon's rank-sum test. Pair-wise comparisons were made using the Mann-Whitney test, whereas differences in the PASI 50 and PASI 75 response rates between groups were examined using the Chi-square test.
RESULTS
A total of 72 patients, 36 in each treatment arm completed the study as scheduled. In each group there were 28 males and 8 females with a mean age of 44.5 (range, 21-69) and 51.2 (range, 25-77) years in the high-dose arm and the low-dose group, respectively.
At week 12 PASI and Skindex-29 scores notably improved as compared to baseline in both treatment arms, without significant differences between the .._------. .
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Week 24 Fig. 1 . Study diagram andjiow chart. 2: PASI 50= obtainment ofthe PASI 50 response; < PASI 50= absence ofthe PASI 50 response QW= once weekly; BIW= twice weekly two groups (Table I) .
The study flow-chart depicting the PASI 50 response rate in the patient sample over the 36week observation period is summarized in Fig. I . In particular, at week 12 the PASI 50 was observed in 33 patients (92%) treated with etanercept 50 mg BIW and in 27 (75%) out of those treated with etanercept 50 mg QW, with the PASI 75 achieved by 19 patients (53%) in the high-dose group vs 13 (36%) in the low-dosage arm. Despite a clear trend towards a higher efficacy of etanercept 50 mg BIW, no statistical difference in the PASI response rate at week 12 was detected between the two groups (p= 0.06 for the PASI 50 and p = 0.23 for the PASI 75).
After decreasing etanercept dosage to 50 mg QW from week 13, all 33 responders (100%) in the highdose group maintained the PASI 50 response at week 24, and 29 ofthem were also PASI 75 responders. For these 33 patients, treatment was then discontinued after week 24 and the PASI 50 response still persisted at week 36 in 23 patients (PASI 75 in 21), whereas 10 patients experienced a relapse of their psoriasis which corresponded to the loss of PASI 50 response. Relapse gradually occurred after an average of 6 weeks, without occurrence of rebound phenomenon or conversion of lesion morphology.
Regarding the low-dose regimen, 8 of 9 patients who did not attain the PASI 50 at week 12 underwent dose escalation to 50 mg BIW for other 12 weeks (one patient was lost to follow-up). At week 24, six of these patients gained the PASI 50 response after etanercept up-dosing, with 3 ofthem also being PASI 75 responders. At week 24, etanercept treatment was stopped in the 6 PASI 50 responders and 4 patients maintained the PASI 50 and 3 the PASI 75 response up to week 36. The initial 27 responders to etanercept 50 mg QW in the initial 12-week phase all continued to receive the same dosage of etanercept up to week 36, with persistence of the PASI 50 response in 100% of cases at week 24 (PASI 75 in 19) and in 25 patients (93%) at week 36 (PASI 75 in 17).
Overall comparison between the different dosage regimens revealed no differences, with the exception of the PASI 50 response at week 36: the proportion of patients without PASI 50 response being significantly smaller in patients continuously treated with etanercept 50 mg QW. In fact, at week 36, only 2 of 27 patients in this group (in which treatment at low dosage continued over the entire 36-week period) lost the PASI 50 response as compared to 10 of 33 patients who were treated with 50 mg BIW for the first 12 weeks and, after dose step-down, stopped treatment from week 25 to week 36 (p=0.027).
Tolerability was very good, without the development of any serious and/or unexpected adverse events during the observation period.
DISCUSSION
Several trials have shown that both continuous and interrupted etanercept therapy are effective and well-tolerated in psoriasis patients, providing significant benefit in skin manifestations and patientreported outcomes (17) (18) (19) .
In our open-label study, both dosages ofetanercept (50 mg QW and 50 mg BIW) for 12 weeks were equally effective in terms of improvement of skin lesions and quality of life.
Previous dose-ranging studies in psoriasis patients have demonstrated that 50 mg BIW leads to achieving a greater and more rapid response than 25 mg BIW (10) (11) . Probably our sample size was not adequate to detect the superiority of high-dosage etanercept over the lower dose at week 12, although a tendency towards better PASI 50 and PASI 75 response rates were observed in patients treated with 50 mg BIW.At the same time, no differences in patient-reported outcomes related to the Skindex-29 questionnaire were seen between the two groups at 12 week. Interestingly, all patients who achieved the PASI 50 after the initial 12 weeks of treatment with either the high or the low dosage continued to be PASI 50 responders at week 24 after further 12 weeks of treatment with 50 mg QW. These results corroborate previous findings indicating the sustained response to etanercept in the majority of patients after dosage step-down (11).
In this pilot study carried out in a real-life setting we reviewed the effect over a 36-week period of different dose regimens of etanercept, resulting in the same cumulative global dose. The use of the low dosage over longer periods (50 mg QW for 36 weeks) has proven able to induce a PASI 50 response rate at week 36 comparable to that achieved with 50 mg BIW for 12 weeks followed by 50 mg QW for a further 12 weeks and subsequent interruption for the final 12 weeks (25 patients vs 23 patients).
Although the PASI 75 is usually considered the primary efficacy parameter in most randomized trials with biological drugs for psoriasis, including etanercept (10-11), we used the PASI 50 response as the primary endpoint in our analysis because this value represents a clinically significant magnitude of psoriasis improvement and in our study, as well as in clinical practice, is the minimum level of improvement required to assess the response to treatment and therefore the feasibility for treatment continuation.
The 'plastic' modularity of etanercept treatment may also have important pharmacoeconomic implications. For instance, the use of 50 mg QW, which has been associated to a favourable costeffectiveness ratio by the NICE guidance (20) , could be considered in most patients at the beginning of therapy, reserving the dose escalation to 50 mg BIW in patients who did not respond at week 12.
Our results confirm that etanercept is very effective and well-tolerated in psoriasis and that the drug dosages and treatment duration may be modulated and adapted to clinical needs in a flexible way.
